Daewoong Net Assets
Daewoong net assets. Based on the latest financial reports, Daewoong (003090) has net assets worth ₩1.88 Trillion KRW (≈ $1.27 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩3.48 Trillion ≈ $2.36 Billion USD) and total liabilities (₩1.60 Trillion ≈ $1.08 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Daewoong growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.88 Trillion |
| % of Total Assets | 53.99% |
| Annual Growth Rate | 9.18% |
| 5-Year Change | 52.75% |
| 10-Year Change | 104.4% |
| Growth Volatility | 16.89 |
Net Assets of Daewoong (2000–2025)
Net assets of Daewoong from 2000 to 2025. This chart illustrates how Daewoong's net assets have evolved over time, based on quarterly financial data. See Daewoong (003090) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Daewoong (2000–2025)
The table below shows the annual net assets of Daewoong from 2000 to 2025. For live market cap and overall valuation, see Daewoong market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.77 Trillion ≈ $1.20 Billion |
+17.63% |
| 2024-12-31 | ₩1.50 Trillion ≈ $1.02 Billion |
+4.57% |
| 2023-12-31 | ₩1.44 Trillion ≈ $973.70 Million |
+12.29% |
| 2022-12-31 | ₩1.28 Trillion ≈ $867.10 Million |
+10.58% |
| 2021-12-31 | ₩1.16 Trillion ≈ $784.11 Million |
+3.59% |
| 2020-12-31 | ₩1.12 Trillion ≈ $756.92 Million |
+8.84% |
| 2019-12-31 | ₩1.03 Trillion ≈ $695.47 Million |
+6.42% |
| 2018-12-31 | ₩964.31 Billion ≈ $653.50 Million |
+2.66% |
| 2017-12-31 | ₩939.31 Billion ≈ $636.55 Million |
+8.64% |
| 2016-12-31 | ₩864.63 Billion ≈ $585.95 Million |
+4.36% |
| 2015-12-31 | ₩828.48 Billion ≈ $561.45 Million |
+16.90% |
| 2014-12-31 | ₩708.73 Billion ≈ $480.30 Million |
+3.15% |
| 2013-12-31 | ₩687.07 Billion ≈ $465.62 Million |
+75.54% |
| 2012-12-31 | ₩391.40 Billion ≈ $265.24 Million |
+16.45% |
| 2011-12-31 | ₩336.10 Billion ≈ $227.77 Million |
-30.66% |
| 2010-12-31 | ₩484.70 Billion ≈ $328.47 Million |
+12.88% |
| 2009-12-31 | ₩429.38 Billion ≈ $290.98 Million |
+4.08% |
| 2008-12-31 | ₩412.53 Billion ≈ $279.57 Million |
+13.50% |
| 2007-12-31 | ₩363.46 Billion ≈ $246.31 Million |
+23.56% |
| 2006-12-31 | ₩294.16 Billion ≈ $199.35 Million |
+17.13% |
| 2005-12-31 | ₩251.13 Billion ≈ $170.19 Million |
+12.78% |
| 2004-12-31 | ₩222.67 Billion ≈ $150.90 Million |
+4.06% |
| 2003-12-31 | ₩213.98 Billion ≈ $145.01 Million |
+4.10% |
| 2002-12-31 | ₩205.55 Billion ≈ $139.30 Million |
-10.14% |
| 2001-12-31 | ₩228.75 Billion ≈ $155.02 Million |
+16.35% |
| 2000-12-31 | ₩196.60 Billion ≈ $133.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daewoong's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 110908144058000.0% over the analyzed period, indicating profitable operations and earnings retention.
Daewoong Net Assets Breakdown (December 2025)
Daewoong net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.11 Trillion | 94.26% |
| Other Components | ₩67.56 Billion | 5.74% |
| Total Equity | ₩1.18 Trillion | 100.00% |
Daewoong Competitors by Market Cap
The table below lists competitors of Daewoong ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sampoerna Agro Tbk
JK:SGRO
|
$447.57 Million |
|
BlackRock Energy and Resources Closed Fund
NYSE:BGR
|
$447.77 Million |
|
Aarti Drugs Limited
NSE:AARTIDRUGS
|
$447.92 Million |
|
Three Stars NM
SHG:603578
|
$448.00 Million |
|
Beijing Tianyishangjia New Material Corp Ltd
SHG:688033
|
$447.53 Million |
|
Shanghai Canature Environmental
SHE:300272
|
$447.39 Million |
|
Northern Arc Capital Ltd
NSE:NORTHARC
|
$447.33 Million |
|
MRV Engenharia e Participações S.A
SA:MRVE3
|
$447.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daewoong's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 996,506,946,100 to 1,176,637,791,550, a change of 180,130,845,450 (18.1%).
- Net income of 175,062,902,530 contributed positively to equity growth.
- Dividend payments of 12,618,334,000 reduced retained earnings.
- New share issuances of 216,104,200 increased equity.
- Other factors increased equity by 17,470,172,720.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩175.06 Billion | +14.88% |
| Dividends Paid | ₩12.62 Billion | -1.07% |
| Share Issuances | ₩216.10 Million | +0.02% |
| Other Changes | ₩17.47 Billion | +1.48% |
| Total Change | ₩- | 18.08% |
Book Value vs Market Value Analysis
This analysis compares Daewoong's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.25x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩12611.48 | ₩15710.00 | x |
| 2018-12-31 | ₩13190.53 | ₩15710.00 | x |
| 2019-12-31 | ₩14533.69 | ₩15710.00 | x |
| 2020-12-31 | ₩16494.66 | ₩15710.00 | x |
| 2021-12-31 | ₩17576.91 | ₩15710.00 | x |
| 2022-12-31 | ₩19932.71 | ₩15710.00 | x |
| 2023-12-31 | ₩22813.07 | ₩15710.00 | x |
| 2024-12-31 | ₩24370.01 | ₩15710.00 | x |
| 2025-12-31 | ₩27990.61 | ₩15710.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daewoong utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.88%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.46%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 2.75x
- Recent ROE (14.88%) is above the historical average (10.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 9.61% | 7.19% | 0.67x | 1.99x | ₩-664.42 Million |
| 2001 | 15.08% | 10.71% | 0.80x | 1.76x | ₩9.91 Billion |
| 2002 | 15.08% | 5.01% | 0.87x | 3.44x | ₩4.70 Billion |
| 2003 | 5.70% | 2.49% | 0.89x | 2.56x | ₩-5.36 Billion |
| 2004 | 9.62% | 3.56% | 0.99x | 2.74x | ₩-476.95 Million |
| 2005 | 11.26% | 3.71% | 1.07x | 2.85x | ₩1.71 Billion |
| 2006 | 15.63% | 4.85% | 1.11x | 2.91x | ₩8.75 Billion |
| 2007 | 16.05% | 4.88% | 1.12x | 2.92x | ₩11.16 Billion |
| 2008 | 7.05% | 2.28% | 1.02x | 3.03x | ₩-6.66 Billion |
| 2009 | 8.31% | 2.61% | 1.09x | 2.93x | ₩-4.07 Billion |
| 2010 | 12.00% | 4.82% | 0.87x | 2.86x | ₩5.40 Billion |
| 2011 | 13.36% | 14.70% | 0.62x | 1.47x | ₩10.87 Billion |
| 2012 | 12.23% | 13.78% | 0.63x | 1.41x | ₩8.04 Billion |
| 2013 | 10.24% | 4.83% | 0.94x | 2.26x | ₩968.29 Million |
| 2014 | 5.53% | 2.66% | 0.88x | 2.35x | ₩-19.23 Billion |
| 2015 | 8.30% | 3.87% | 0.80x | 2.67x | ₩-7.92 Billion |
| 2016 | 4.08% | 1.95% | 0.69x | 3.02x | ₩-28.75 Billion |
| 2017 | 12.16% | 5.89% | 0.73x | 2.84x | ₩11.79 Billion |
| 2018 | 5.24% | 2.43% | 0.77x | 2.80x | ₩-27.10 Billion |
| 2019 | 9.95% | 4.57% | 0.82x | 2.66x | ₩-323.84 Million |
| 2020 | 14.35% | 7.26% | 0.74x | 2.68x | ₩29.85 Billion |
| 2021 | 10.79% | 5.21% | 0.78x | 2.65x | ₩5.75 Billion |
| 2022 | 12.37% | 6.04% | 0.79x | 2.60x | ₩19.68 Billion |
| 2023 | 16.33% | 8.42% | 0.77x | 2.52x | ₩59.19 Billion |
| 2024 | 5.81% | 2.99% | 0.71x | 2.73x | ₩-41.77 Billion |
| 2025 | 14.88% | 8.46% | 0.64x | 2.75x | ₩57.40 Billion |
Industry Comparison
This section compares Daewoong's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $482,635,194,011
- Average return on equity (ROE) among peers: 4.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daewoong (003090) | ₩1.88 Trillion | 9.61% | 0.85x | $447.54 Million |
| Dongwha Pharm.Co.Ltd (000020) | $360.13 Billion | 4.96% | 0.24x | $98.24 Million |
| Yuhan Corp. (000100) | $862.60 Billion | 14.22% | 0.20x | $3.80 Billion |
| Yuhan Corp Preferred (000105) | $1.94 Trillion | 5.30% | 0.27x | $45.29 Million |
| Yuyu Pharma (000220) | $78.29 Billion | 7.52% | 0.42x | $40.47 Million |
| Yuyu Pharma Inc (000225) | $140.54 Billion | 5.80% | 0.47x | $13.42 Million |
| Yuyu Pharma Inc (000227) | $117.04 Billion | 1.10% | 0.32x | $32.52 Million |
| Ildong Holdings Co Ltd (000230) | $172.99 Billion | 13.36% | 0.64x | $44.50 Million |
| Samil Pharm (000520) | $56.08 Billion | -15.27% | 1.64x | $107.04 Million |
| Donga Socio Holdings (000640) | $914.25 Billion | 3.56% | 0.60x | $380.90 Million |
| Jw Pharmac (001060) | $188.54 Billion | -0.51% | 2.36x | $349.95 Million |
About Daewoong
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Phar… Read more